This record was last updated September 22, 2025 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to learn if dapagliflozin drug has a cardioprotective effect against anthracyclines-induced cardiotoxicity. It will also learn about the safety of dapagliflozin drug.
Aim of the study:
Evaluate cardioprotective effect and safety of dapagliflozin against anthracyclines-induced cardiotoxicity.
The main questions it aims to answer are:
1. Does the drug lower the cardiotoxicity which induced by anthracyclines?
2. What medical problems do participants have when taking dapagliflozin drug?
Treatment
1. Anthracyclines by 4 cycles included doxorubicin 50-60 mg/m2 with cyclophosphamide 600 mg as a combination or epirubicin 90-100 mg/m2 with cyclophosphamide 600 mg as a combination.
2. Dapagliflozin 10 mg tablet orally, once daily. Started 7 days before the first cycle of anthracyclines till the end of last anthracyclines dose.
Protocol Amendment History
3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-07-01; most recent amendment 2025-09-16.
Status change: Not Yet Recruiting → Recruiting2024-09-22